Cargando…
A case of antithyroid drug‐induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment
Agranulocytosis is a rare side effect of antithyroid drugs (ATD) that usually develops within the first 3‐6 months after starting treatment. We present a 64‐year‐old patient who developed agranulocytosis after starting ATD to treat relapsed Graves' disease. This patient had tolerated the first...
Autores principales: | Kim, Hyunsam, Lee, Jeongmin, Ha, Jeonghoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132132/ https://www.ncbi.nlm.nih.gov/pubmed/30214745 http://dx.doi.org/10.1002/ccr3.1644 |
Ejemplares similares
-
THU670 Serum TSI Concentration In Patients With Graves’ Disease Undergoing Maintenance-dose Of Antithyroid Drug (ATD) And Its Relationship With Disease Relapse After ATD Withdrawal
por: Nhat Nguyen, Phong Vu, et al.
Publicado: (2023) -
Antithyroid Drug-Induced Agranulocytosis: A Case Report
por: MacKay, Micaela, et al.
Publicado: (2023) -
Antithyroid Drug Treatment in Graves’ Disease
por: Chung, Jae Hoon
Publicado: (2021) -
ATD Talent Management Handbook
por: Bickham, Terry
Publicado: (2015) -
Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and Management
por: Vicente, Nuno, et al.
Publicado: (2017)